The Problem of Hispanic/Latinx Under-Representation in Cancer Clinical Trials
JCO Oncol Pract
.
2022 May;18(5):380-384.
doi: 10.1200/OP.22.00214.
Authors
Manuel R Espinoza-Gutarra
1
,
Narjust Duma
2
,
Paula Aristizabal
3
4
5
,
Barbara Segarra-Vazquez
6
,
Hala Borno
7
,
Chanita Hughes Halbert
8
,
Melissa A Simon
9
,
Ana I Velazquez
7
Affiliations
1
Indiana University School of Medicine, Indianapolis, IN.
2
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
3
University of California San Diego, Department of Pediatrics, Division of Pediatric Hematology/Oncology, San Diego, CA.
4
Rady Children's Hospital San Diego, Peckham Center for Cancer and Blood Disorders, San Diego, CA.
5
University of California San Diego Moores Cancer Center, Population Sciences Disparities and Community Engagement, San Diego, CA.
6
University of Puerto Rico Medical Sciences Campus, San Juan, PR.
7
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
8
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
9
Northwestern University, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.
PMID:
35544652
DOI:
10.1200/OP.22.00214
No abstract available
Publication types
Editorial
MeSH terms
Clinical Trials as Topic*
Hispanic or Latino*
Humans
Neoplasms* / ethnology
Neoplasms* / therapy
Patient Participation*
Grants and funding
K08 CA230306/CA/NCI NIH HHS/United States